Published as: *Science*. 2011 December 2; 334(6060): 1241–1245.

Functional Links Between A β Toxicity, Endocytic Trafficking and Alzheimer's Disease Risk Factors in Yeast

Sebastian Treusch^{1,2}, Shusei Hamamichi^{1,3}, Jessica L. Goodman¹, Kent E.S. Matlack^{1,2}, Chee Yeun Chung¹, Valeriya Baru^{1,2}, Joshua M. Shulman^{4,5}, Antonio Parrado⁶, Brooke J. Bevis¹, Julie S. Valastyan^{1,2}, Haesun Han¹, Malin Lindhagen-Persson⁷, Eric M. Reiman^{8,9}, Denis A. Evans¹⁰, David A. Bennett¹¹, Anders Olofsson⁷, Philip L. DeJager^{4,5}, Rudolph E. Tanzi⁶, Kim A. Caldwell³, Guy A. Caldwell³, and Susan Lindquist^{1,2,*}

¹Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA

²Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

³Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL 35487, USA

⁴Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology & Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

⁵Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA

⁶Genetics and Aging Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA

⁷Department of Medical Biochemistry and Biophysics, Umea University, Umea, Sweden

⁸Neurogenomics Division, Translational Genomics Research Institute and Arizona Alzheimer's Consortium, Phoenix, AZ 85004, USA

⁹Banner Alzheimer's Institute and Department of Psychiatry, University of Arizona, Phoenix, AZ 85006, USA

¹⁰Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA

¹¹Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA

Abstract

A β (amyloid beta peptide) is an important contributor to Alzheimer's disease (AD). We modeled A β toxicity in yeast by directing the peptide to the secretory pathway. A genome-wide screen for toxicity modifiers identified the yeast homolog of phosphatidylinositol binding clathrin assembly protein (*PICALM*) and other endocytic factors connected to AD whose relationship to A β was previously unknown. The factors identified in yeast modified A β toxicity in glutamatergic neurons

*To whom the correspondence should be addressed. lindquist_admin@wi.mit.edu.

Supplemental data are available in the Supplemental Online Material.

Supplemental Online Material

Materials and Methods

Figs. S1 to S7

Tables S1 to S7

References

of *Caenorhabditis elegans* and in primary rat cortical neurons. In yeast, A β impaired the endocytic trafficking of a plasma membrane receptor, which was ameliorated by endocytic pathway factors identified in the yeast screen. These links between A β , endocytosis, and human AD risk factors can be ascertained using yeast as a model system.

Yeast cells lack the specialized processes of neuronal cells and the cell-cell communications that modulate neuropathology. However, the most fundamental features of eukaryotic cell biology evolved before the split between yeast and metazoans. Yeast studies of the cell cycle, DNA damage repair and checkpoints produced pivotal advances in cancer biology (1). More recently, the conservation of protein-homeostasis networks, vesicular trafficking, mitochondrial biology, autophagy, and apoptosis facilitated the development of yeast models for protein-misfolding pathologies (1). When human diseases impinge on common features of eukaryotic cell biology, yeast's unequaled toolkit offers an attractive discovery platform, as established for multiple aspects of α -synuclein toxicity (2–7).

Here, we wanted to create a yeast model of cellular toxicities elicited by the amyloid β (A β) peptide. According to the still hotly debated “amyloid cascade” hypothesis, A β is causal in both sporadic and familial Alzheimer's Disease (AD) (8). The oligomeric forms of the peptide appear to be the most toxic (9–12). Similar toxic oligomers, formed by unrelated proteins but all recognized by the same conformation-specific antibody, are associated with other neurodegenerative diseases and with yeast prions (13, 14). Thus, the toxicity of such oligomers is an ancient protein-folding problem.

In addition to A β , neurofibrillary tangles (NFTs) of tau, a microtubule-binding protein, are hallmarks of AD pathology (15). A β seems to act upstream of tau (16, 17). Genetic AD risk factors are now being identified through genome-wide association studies (GWAS), but their relationship to A β is unknown.

A yeast model of A β toxicity

The most toxic form of A β , A β 1–42, is generated by proteolytic cleavage of APP, the transmembrane amyloid precursor protein (18, 19). APP processing occurs in the secretory pathway, which releases A β into the trans-Golgi, endosomal compartments, and extracellular space. A β then interacts with the plasma membrane and is subject to endocytosis and further vesicular trafficking (18). To recapitulate this multi-compartment trafficking in yeast, we fused an ER targeting signal to the N-terminus of A β 1–42 (referred to as ssA β 1–42, Fig. 1A). Without an ER retention signal, after cleavage of the signal sequence A β 1–42 should simply transit through the secretory pathway to the plasma membrane (20). The yeast cell wall will restrain secreted peptides from diffusing into the culture medium, allowing A β to interact with the plasma membrane, undergo endocytosis, and thereby transit through endocytic compartments potentially relevant to AD (Fig. S1A).

When expressed from a galactose-inducible (*GALI*) promoter and a multi-copy plasmid, ssA β 1–42 decreased cell growth (Fig. 1A). Using the same plasmid, A β 1–40 was less toxic, as were Pdi1 (an ER resident protein), BPTI (a small protein commonly used to study secretion), and even BPTI^{C51A} (a variant that misfolds in the ER (21)) (Fig. 1A).

For genetic screens, strains with uniform stable ssA β 1–42 expression were constructed by integrating tandem copies in the genome (Fig. S1B). We targeted a locus where insertions have no deleterious consequences and selected strains that grew slowly upon galactose induction, but with no major increase in lethality (Fig. S1C and Table S1). The peptide produced was of the expected size for processed A β (Fig. S1D), verified by mass

spectrometry (Fig. S1E). Localization to secretory compartments was confirmed by immunofluorescence (Fig. 1B).

When lysates were not subjected to boiling, which disrupts oligomeric species, we detected A β oligomers on Bis-Tris gels (Fig. S1D). These forms reacted more strongly with the antibody NAB61, which preferentially recognizes toxic A β oligomers in AD patients (Fig. 1C) (10). These species disappeared upon boiling in lithium dodecyl sulfate (LDS) buffer. Assaying lysates by size-exclusion chromatography with a monoclonal IgM anti-A β antibody specific for A β oligomers detected a broad range of oligomeric species (Fig. 1D and Fig. S1F) (22). Eliminating preparation artifacts, these were not seen when purified monomeric A β peptide was added to control cultures prior to lysis (Fig. 1D). In strains that produced the same levels of A β 1-40 and 1-42 monomer after boiling (Fig. S1G), oligomers were much more abundant for A β 1-42 prior to boiling (Fig. 1E). Thus, oligomeric A β forms contribute to toxicity in yeast, as in neurons.

Screen for genetic modifiers of A β toxicity

We transformed a screening strain with an overexpression library of 5532 full length open reading frames (ORFs) (~90% of yeast ORFs) under control of the same promoter used for ssA β 1-42 (Fig. S2A). Individual transformants were arrayed in media that prevented induction of either ssA β 1-42 or the library constructs, then plated (four replicates each) onto several types of inducing media, chosen to support different levels of mitochondrial respiration (Fig. S2B; (23), Table S2). Intermediate levels of A β toxicity enabled the identification of enhancers and suppressors in the same screen (Fig. S1B; (23), Table S2). Genes that decreased or increased growth (Fig. S2B) were retested in an independently derived screening strain. Secondary screens eliminated genes that simply altered expression of A β from the *GAL1* promoter (Fig. S3) or growth in the absence of A β .

We identified 23 suppressors and 17 enhancers (Table S2). Only a few modifiers were strongly affected by the state of respiration (Table S2). The screen hits comprised a wide range of cellular functions. Numerous hits had sequence similarity to human genes, and twelve had very clear human homologs (determined by HomoloGene or by analogous functionality [*SLA1* – *SH3KBPI*] (24)) (Table 1). We focused further analysis on these.

Three of these twelve genes had functions related to clathrin-mediated endocytosis (*YAP1802*, *INP52* & *SLA1*; $P=3.89\text{e-}4$) and seven were functionally associated with the cytoskeleton (*YAP1802*, *INP52*, *SLA1*, *CRM1*, *GRR1*, *KEM1* & *RTS1*; $P=6.06\text{e-}8$). None were identified in our previous screen for modifiers of α -syn toxicity (5, 7), establishing their specificity for the type of toxicity caused by A β 1-42.

Modifiers of A β toxicity are associated with AD susceptibility

Several human homologs of our yeast hits had connections to human AD risk factors, particularly those involved in clathrin-mediated endocytosis (Table 1). The human homolog of yeast *YAP1802*, *PICALM*, is one of the most highly confirmed risk factors for sporadic AD (25, 26). Another AD risk factor, *BINI*, is involved in synaptic vesicle endocytosis and is believed to interact with synaptojanin, the human homolog of yeast *INP52* (27). The functional homolog of yeast *SLA1*, *SH3KBPI* (28), directly interacts with the risk factor *CD2AP* (29, 30). *CD2AP* links endocytosis to cytoskeletal dynamics and our other major class of screen hits.

To assess the potential clinical relevance of other screen hits with highly conserved human homologs we examined association with AD susceptibility using data from a published family-based GWAS (31, 32). Using a family-based association test, we discovered a

suggestive association of *XPO1* (*CRM1* homolog, rs6545886, $P=0.003$) with AD susceptibility ((23), Table S3).

Next, we leveraged genotyping with extensive clinical and pathological data from two large epidemiological studies of aging, cognition, and AD (33, 34) ((23), Table S4–7). Using a quantitative summary measure of global AD pathologic burden available in these cohorts, counting both amyloid plaques and NFTs, we found that two additional loci identified by our yeast screen, *ADSSL1* (*ADE12* homolog, rs1128880, $P=0.001$) and *RABGEF1* (*VPS9* homolog, rs17566701, $P=0.002$) showed evidence of association with AD neuropathology (Table S7). Both loci also harbored suggestive association signals with episodic memory decline (Table S6). Thus, our yeast screen connects multiple human AD risk factors, and suggested risk factors, to A β toxicity.

C. elegans model of A β toxicity

To directly test our modifiers for effects on A β toxicity in neurons, we created a transgenic *C. elegans* model that expressed A β 1-42 in glutamatergic neurons, a neuronal subtype particularly vulnerable in AD. (A previous model expressed A β in body-wall muscles (35).) We used the *eat-4* promoter, which regulates the BNPI glutamate transporter and, again, targeted A β to the secretory pathway (35). The A β transgene was integrated into chromosomal DNA to ensure the same A β 1-42 expression levels in all animals.

C. elegans has highly stereotyped cell lineages. Wild-type worms invariably have five glutamatergic neurons in their tails, which we visualized with *eat-4*-regulated GFP. Crossing worms expressing ssA β to worms carrying this reporter resulted in the loss of GFP-marked glutamatergic neurons in an age-related manner: at day three only 48% of worms had five intact glutamatergic neurons, and at day seven only 25% did (Fig. 2A).

To test the effects of our screen hits (Table 1) we established three independent transgenic worm lines for each gene, again expressing the protein from the *eat-4* promoter. Unrelated control proteins mCherry and LacZ had no effect on A β toxicity. All three *C. elegans* homologs of the genes involved in clathrin-mediated endocytosis, *unc-11*, *unc-26*, and *Y44E3A.4*, increased the percentage of worms with five intact glutamatergic neurons (Fig. 2).

Finally, we tested four hits, three suppressors and one enhancer, involved in a diverse array of pathways. The yeast *RTS1* gene encodes a phosphatase regulatory subunit that controls several stress-response pathways. The *ADE12* gene product catalyzes the first step in the synthesis of adenosine monophosphate from inosine 5-monophosphate. The *C. elegans* homologs of each gene suppressed the A β -induced loss of glutamatergic neurons (Fig. 2A). We were unable to clone the worm homologs of *GRR1*, *VPS9*, or *CRM1*. However, *CRM1* encodes a highly conserved nuclear export receptor. Expression of *CRM1*'s human homologue, *XPO1*, protected nematode glutamatergic neurons from A β (Fig. 2A). *PBS2*/*MAP2K4*, a MAP kinase involved in stress responses, increased neuronal loss (Fig. 2).

The effect of each gene was statistically significant ($p < 0.05$) for both the modest neuronal toxicity evinced at three days and the more severe toxicity at seven days. Importantly, the modifiers did not alter the levels of A β mRNA, which we tested by semi-quantitative RT-PCR (Fig. S5). Thus, every gene we tested in *C. elegans* glutamatergic neurons modified A β toxicity in the same direction (suppression vs. enhancement) as they did in yeast.

***PICALM* suppresses the toxicity of soluble A β oligomers with rat cortical neurons**

PICALM is one of the most highly validated AD risk factors and its efficacy in our yeast and nematode models strongly suggests it alters A β toxicity. Modeling this in cultured mammalian neurons is not trivial, because any A β peptide expressed in the secretory pathway would simply diffuse away from the cell. Exogenously applied, preformed oligomeric A β species are often employed to model toxicity (13, 36), but their relevance is highly debated. We reasoned that a positive result for the highly validated AD risk factor *PICALM* might not only validate this assay but confirm the role of *PICALM* in A β detoxification.

We analyzed cortical neurons, a neuronal population particularly relevant to AD. Embryos from female rats with timed pregnancies were harvested at 18 days of gestation. Cortices dissected from these embryos were dissociated, plated and cultured for up to 21 days (23). The production of toxic A β oligomers is notoriously variable. We prepared oligomers according to several published methods, characterized them biochemically, and tested them for producing consistent levels of toxicity in our cortical neuronal preparations (Fig. 3, Fig. S6 and Fig. S7). The loss of toxicity when the same samples were allowed to form A β fibers (Fig. S6A and S6C) confirmed the importance of the oligomeric species (Fig. S6D).

Next, we infected neurons with lentiviruses engineered to express GFP or *PICALM*. When A β oligomers were added to these neurons, GFP had no effect but *PICALM* partially rescued the cells from A β induced cell death in a dose-dependent manner (Fig. 3). Rescue was significant whether assayed by cellular ATP levels (Fig. 3A) or by counting the number of MAP2 positive neurons (Fig. 3B and Fig. 3C). As previously described for midbrain neurons (7), we found that *RAB1* protected cortical neurons from α -syn toxicity when this protein was expressed intracellularly by viral transfection. However, *RAB1* was ineffective against A β oligomers, confirming the specificity of *PICALM* for the type of toxicity caused by A β oligomers (Fig. S7).

Effect of A β on endocytosis and trafficking

The role of *PICALM* in AD is unknown, but it has been postulated to affect disease by modifying APP trafficking (25). However, our experiments in yeast, nematode and rat neurons clearly establish *PICALM* as a modifier of A β toxicity itself. To investigate the mechanism for *PICALM* and the other modifiers that affect clathrin-mediated endocytosis, we returned to yeast.

One possibility is that clathrin-mediated endocytosis modulates A β toxicity simply by shunting toxic A β species to the lysosomal/vacuolar system for degradation. However, immunoblotting of yeast lysates indicated these modifiers had little effect on A β levels (Fig. S4). Alternatively, if A β specifically perturbs endocytic homeostasis, up-regulation of this pathway might ameliorate the defect.

To determine if A β altered clathrin distributions, we used a strain in which endogenous clathrin light chain (Clc1) was tagged with GFP, a fully functional fusion. A control strain exhibited the expected distribution of Clc1-GFP foci (37). A β perturbed clathrin localization, increasing both the number and brightness of foci, but decreasing their average size (Fig. 4A).

Such a pattern might indicate a defect in clathrin-mediated secretion as well as in endocytosis. To test effects of A β on secretion, we used a halo assay for secretion of the α -

factor mating pheromone. As a control, we also tested the effects of α -syn expression, which produces a strong defect in secretion (7) (Fig. 4B). Unlike α -syn, A β did not inhibit secretion (Fig. 4B).

To assess the impact of A β on clathrin-mediated endocytosis specifically, we examined the well-characterized substrate Ste3, a member of the highly conserved G-protein coupled receptor family. Ste3 is targeted to the plasma membrane. In the absence of its ligand, the yeast mating-factor, it is constitutively endocytosed and degraded in the vacuole (38). As expected, a Ste3-YFP fusion was primarily localized to the vacuole in a control strain (Fig. 4C). In A β -expressing strains, endocytic trafficking of Ste3-YFP was profoundly perturbed and the protein was localized to numerous foci ((23), Fig. 4C). A β expression resulted in a reduction of vacuolar organelle size without a disruption in morphology, consistent with reduced delivery of cargo to this organelle. Finally, we tested the effects of the three A β toxicity suppressors that function in endocytic trafficking, *YAP1802*, *INP52*, and *SLA1*. Each partially reversed the defect in Ste3-YFP trafficking (Fig. 4C).

Conclusions and Perspectives

Our yeast model allowed us to conduct an unbiased screen of an entire genome for modifiers of A β toxicity. The emergence of three different genes involved in the process of clathrin-mediated endocytosis from nearly 6,000 tested ORFs confirms that the A β peptide in our model is trafficking through the secretory compartments as expected. More importantly, the ability of endocytic genes to rescue A β toxicity, together with the effects of A β on clathrin localization and the trafficking of a G protein-coupled receptor, establish that within these highly diverse organisms clathrin-mediated endocytosis is a critical point of vulnerability to A β .

A β oligomers have been reported to increase endocytosis in cultured cells (39), and human-induced neuronal cells derived from the fibroblasts of AD patients exhibit defects in endocytosis (40). Mechanistically, in our A β -expressing cells, the increased number of clathrin foci, the internalized foci of Ste3, and the effects of genetic modifiers on vacuolar localization all suggest that A β affects this pathway by interfering with the ability of endocytosed transmembrane receptors to reach their proper destinations.

PICALM, as well as two genes whose protein products (*BINI* and *CD2AP*) interact with hits from our screen are AD risk factors. Given the diversity of pathologies however, their connection to A β toxicity was unknown. Our work in yeast, nematodes, and rat cortical neurons clearly places these factors within the A β cascade, linking A β to the genetics of sporadic AD.

Neurons are particularly vulnerable to perturbations in the homeostasis of endocytosis, because they must constantly recycle both neurotransmitters and their receptors (41). A β interacts with, and alters signaling by, a variety of neuronal receptors (42). We propose that the conformational flexibility of these oligomers allows them to interact rather promiscuously with conformationally flexible unliganded receptors, which, in turn, disrupts endocytic homeostasis.

Our yeast screen also identified seven conserved genes functionally associated with the cytoskeleton. Because yeasts do not express tau, our findings may indicate that the connection between A β toxicity and the cytoskeleton is more deeply rooted than tau alone, probably involving clathrin-mediated endocytosis. In analyzing human GWAS data we also uncovered suggestive associations between AD and three other genes, *XPO1*, *ADSSL1*, and *RABGEF1*, and confirmed their A β relationships in yeast and nematode.

The treatments available for AD are few and their efficacy limited. Determining how best to rescue neuronal function in the context of the whole brain is a problem of staggering proportions. Our yeast model provides a tool for identifying genetic leads, investigating their mechanisms of action, and screening for genetic and small molecule modifiers of this devastating and etiologically complex disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank L. Chibnik, B. Keenan and D. Ng for helpful discussions. D. Wittrup, V. Lee, M. Vidal and C. Link for materials, J. Corneveaux, M. Huentelman, and other Translational Genomics investigators for assistance with the human study cohorts and participants in the Religious Orders Study and the Rush Memory and Aging Project. This work was supported by an HHMI Collaborative Innovation Award, NRSA fellowship F32 NS067782-02, the Cure Alzheimer's Fund, NIH grants K08AG034290, P30AG10161, R01AG15819, and R01AG17917, the Kempe foundation and Alzheimerfonden.

REFERENCES

1. Khurana V, Lindquist S. Modelling neurodegeneration in *Saccharomyces cerevisiae*: why cook with baker's yeast? *Nat Rev Neurosci*. 2010; 11:436. [PubMed: 20424620]
2. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science*. 2003; 302:1772. [PubMed: 14657500]
3. Thayanidhi N, et al. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. *Mol Biol Cell*. 2010; 21:1850. [PubMed: 20392839]
4. Winslow AR, et al. alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. *J Cell Biol*. 2010; 190:1023. [PubMed: 20855506]
5. Gitler AD, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. *Nat Genet*. 2009; 41:308. [PubMed: 19182805]
6. Su LJ, et al. Compounds from an unbiased chemical screen reverse both ER-to- Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. *Dis Model Mech*. 2009; 3:194. [PubMed: 20038714]
7. Cooper AA, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science*. 2006; 313:324. [PubMed: 16794039]
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. 2002; 297:353. [PubMed: 12130773]
9. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. *Neurobiol Aging*. 2007; 28:1297. [PubMed: 16876915]
10. Lee EB, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. *J Biol Chem*. 2006; 281:4292. [PubMed: 16361260]
11. Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med*. 2008; 14:837. [PubMed: 18568035]
12. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry*. 2000; 39:10831. [PubMed: 10978169]
13. Kaye R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*. 2003; 300:486. [PubMed: 12702875]
14. Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. *Science*. 2004; 304:1793. [PubMed: 15155912]

15. LaFerla FM. Pathways linking Abeta and tau pathologies. *Biochem Soc Trans.* 2010; 38:993. [PubMed: 20658991]
16. Ittner LM, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell.* 2010; 142:387. [PubMed: 20655099]
17. Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science.* 2007; 316:750. [PubMed: 17478722]
18. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. *J Biol Chem.* 2008; 283:29615. [PubMed: 18650430]
19. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. *Cell.* 2007; 131:215. [PubMed: 17956719]
20. Pelham HR. Control of protein exit from the endoplasmic reticulum. *Annu Rev Cell Biol.* 1989; 5:1. [PubMed: 2688704]
21. Kowalski JM, Parekh RH, Wittrup KD. Secretion efficiency in *Saccharomyces cerevisiae* of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. *Biochemistry.* 1998; 37:1264. [PubMed: 9477952]
22. Lindhagen-Persson M, Brannstrom K, Vestling M, Steinitz M, Olofsson A. Amyloid-beta oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies. *PLoS One.* 2010; 5:e13928. [PubMed: 21085663]
23. Please refer to Supplemental Online Material.
24. Stamenova SD, Dunn R, Adler AS, Hicke L. The Rsp5 ubiquitin ligase binds to and ubiquitinates members of the yeast CIN85-endophilin complex, Sla1-Rvs167. *J Biol Chem.* 2004; 279:16017. [PubMed: 14761940]
25. Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1088. [PubMed: 19734902]
26. Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1094. [PubMed: 19734903]
27. Ramjaun AR, Micheva KD, Bouchelet I, McPherson PS. Identification and characterization of a nerve terminal-enriched amphiphysin isoform. *J Biol Chem.* 1997; 272:16700. [PubMed: 9195986]
28. Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH. Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation. *J Cell Sci.* 2007; 120:2366. [PubMed: 17606992]
29. Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011; 43:429. [PubMed: 21460840]
30. Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet.* 2011; 43:436. [PubMed: 21460841]
31. Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet.* 2008; 83:623. [PubMed: 18976728]
32. Blacker D, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. *Neurology.* 1997; 48:139. [PubMed: 9008509]
33. Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. *Neurology.* 2009; 72:1495. [PubMed: 19398704]
34. Shulman JM, et al. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. *PLoS ONE.* 2010; 5:e1124.
35. Link CD. Expression of human beta-amyloid peptide in transgenic *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A.* 1995; 92:9368. [PubMed: 7568134]
36. Bozyczko-Coyne D, et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. *J Neurochem.* 2001; 77:849. [PubMed: 11331414]
37. Sun Y, Carroll S, Kaksonen MY, Toshima J, Drubin DG. PtdIns(4,5)P2 turnover is required for multiple stages during clathrin- and actin-dependent endocytic internalization. *J Cell Biol.* 2007; 177:355. [PubMed: 17452534]

38. Maldonado-Baez L, et al. Interaction between Epsin/Yap180 adaptors and the scaffolds Ede1/Pan1 is required for endocytosis. *Mol Biol Cell*. 2008; 19:2936. [PubMed: 18448668]
39. Minano-Molina AJ, et al. Soluble Oligomers of Amyloid- β Peptide Disrupt Membrane Trafficking of α -Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Contributing to Early Synapse Dysfunction. *J Biol Chem*. 2011; 286:27311. [PubMed: 21665950]
40. Qiang L, et al. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. *Cell*. 2011; 146:359. [PubMed: 21816272]
41. Jung N, Haucke V. Clathrin-mediated endocytosis at synapses. *Traffic*. 2007; 8:1129. [PubMed: 17547698]
42. Verdier Y, Zarandi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. *J Pept Sci*. 2004; 10:229. [PubMed: 15160835]

Figure 1.

Expression of Aβ in the yeast secretory pathway. **(A)** Comparison of ssAβ 1-42 toxicity with ssAβ 1-40, ssBPTI (WT and C51A) and Pdi1. Proteins were expressed using the inducible *GAL1* promoter and a high copy number plasmid. Strains carrying the plasmids were serially diluted and spotted on inducing (galactose) and non-inducing (glucose) media. **(B)** Immunostaining for ssAβ 1-42 reveals localization to the ER/secretory pathway. Aβ was detected in the ER (ring surrounding the nucleus, stained blue with DAPI) and in small foci throughout the cell. The scale bar is 5μm. All figures are on the same scale. **(C)** Immunoblot with NAB61, an antibody specific for soluble Aβ oligomers, detects oligomers in unboiled

samples. An immunoblot with the 6E10 A β -specific antibody is shown for reference. **(D)** An indirect ELISA assay using a monoclonal A β oligomer-specific antibody detects A β oligomers in the 1 $\times$ ssA β strain and, more so, in the two screening strains (n=5; error bars too small to be visible; **: $p < 0.01$, based on Dunnett's test). **(E)** A β 1-40 and A β 1-42 expression was detected by immunoblot analysis of unboiled lysates using 6E10.

Figure 2.

Hits from the yeast screen modify the toxicity of $A\beta$ in *C. elegans* glutamatergic neurons in the same direction as in yeast. **(A)** A new animal model of $A\beta$ toxicity. $A\beta$ 1-42, carrying a signal sequence targeting it to the secretory compartment, was expressed in glutamatergic neurons that also expressed GFP. Neuronal death increased from 50% at day 3 to 75% at day 7, establishing that this worm model exhibits age-dependent neurodegeneration. Control genes mCherry and LacZ had no effect on $A\beta$ -induced neurodegeneration. Measurements are relative to the number of neurons found in WT worms expressing only GFP. Bar patterns indicate distinct functional categories (crosshatches for endocytic genes). The genetic modifiers tested influenced $A\beta$ toxicity significantly ($p < 0.05$, Student's *t*-test). *XPO1* was derived from human cDNA. For each worm (w) or human (h) gene, three transgenic lines were established and 90 worms examined for each. **(B)** Representative examples of worms scored in Fig. 2A at the third day of development. Arrowheads indicate neuronal cell bodies, marked by transgenic expression of GFP.

Figure 3.

PICALM protects cultured rat cortical neurons from exogenously applied Aβ oligomers. Cortical neuron cultures prepared from rat embryos at embryonic day 18 were cultured for 5 days, transduced, cultured for 13 days, and then incubated for 20 hours with 750nM of soluble Aβ oligomers prepared from synthetic peptide (23). Infection with a *PICALM* lentiviral construct diminished toxicity in a dose-dependent, statistically significant manner. Cell viability was assessed by both ATP content (A) and MAP2 positive cell counting (B and C). Data are representative of three independent experiments and shown as mean $\pm$ SEM (*: $p < 0.05$; **: $p < 0.01$, based on Dunnett's test for (A) and two-tail *t*-test for (B)).

Figure 4.

Aβ causes defects in endocytosis and receptor protein trafficking. **(A)** In a yeast strain with GFP-tagged clathrin light chain (Clc1-GFP), ssAβ 1-42 caused an increase in Clc1-GFP foci. **(B)** A halo assay, which measures secretion of the α-factor pheromone, was used to assess secretion. In the screening strain ssAβ 1-42 diminished growth but did not reduce secretion compared to the vector control. In contrast, a strain expressing α-syn, which is known to impede ER-Golgi trafficking, exhibits a strong defect in secretion. **(C)** Aβ 1-42 caused a defect in the normal trafficking of Ste3 to the vacuole. A Ste3-YFP fusion is normally trafficked to the vacuole. Aβ-expressing cells showed accumulation of Ste3-YFP in cytoplasmic foci. Co-expression of *YAP1802*, *INP52*, and *SLA1* partially restored Ste3-YFP trafficking to the vacuole. A constitutively-expressed Ste3-YFP gene was integrated in the genome of the control and screening strain. Scale bars are 5μm. All images are on the same scale.

Table 1

Genes that modify A β toxicity. Yeast genes with clear nematode and human homologs were identified in an unbiased screen of 5,532 single copy plasmids carrying yeast ORFs under the control of the *GAL1* promoter in three independent screens in three inducing medias (23).

Yeast A β Suppressors	Cellular Function	<i>C. elegans</i> Homolog	Human Homolog	Connection of human homologs to AD Risk
<i>YAP1802</i>	Endocytosis	<i>unc-11</i> [*]	<i>PICALM</i>	Validated risk factor ^{1,2}
<i>INP52</i>	Endocytosis	<i>unc-26</i> [*]	<i>SYNJ1</i>	Interacts with validated risk factor <i>BINI</i> (27)
<i>SLA1</i>	Endocytosis	<i>Y44E3A.4</i> [*]	<i>SH3KBP1</i>	Interacts with validated risk factor <i>CD2AP</i> (28)
<i>RTS1</i>	Phosphatase regulation	<i>pptr-2</i> [*]	<i>PPP2R5C</i>	
<i>ADE12</i>	Adenylosuccinate synthesis	<i>C37H5.6b</i> [*]	<i>ADSSL1</i>	Potential risk factor, this study ³
<i>CRM1</i>	Nuclear protein export	<i>xpo-1</i> [*]	<i>XP01</i>	Potential risk factor, this study ²
<i>GRR1</i>	Ubiquitination	<i>C02F5.7</i>	<i>FBXL2</i>	
<i>VPS9</i>	Vesicle transport	<i>rabx-5</i>	<i>RABGEF1</i>	Potential risk factor, this study ³
Yeast Aβ Enhancers				
<i>PBS2</i>	Osmotic stress response	<i>mkk-4</i> [*]	<i>MAP2K4</i>	Activated by A β oligomers in cortical neurons (36)
<i>KEM1</i>	RNA processing	<i>xrn-1</i>	<i>XRN1</i>	
<i>MVP1</i>	Vacuolar sorting	<i>lst-4</i>	<i>SNX8</i>	
<i>PMT2</i>	Mannosylation	-	<i>POMT2</i>	

^{*} Genes tested in the *C. elegans* model

¹Table S3

²Table S6

³Table S7